1. Home
  2. UFI vs MAIA Comparison

UFI vs MAIA Comparison

Compare UFI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unifi Inc. New

UFI

Unifi Inc. New

HOLD

Current Price

$5.54

Market Cap

76.4M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.13

Market Cap

69.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UFI
MAIA
Founded
1969
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.4M
69.2M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
UFI
MAIA
Price
$5.54
$1.13
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $12.00
AVG Volume (30 Days)
60.1K
★ 522.0K
Earning Date
11-03-2026
11-06-2026
Dividend Yield
★ 30.77%
N/A
EPS Growth
N/A
★ 33.33
EPS
N/A
★ N/A
Revenue
★ $531,303,000.00
N/A
Revenue This Year
$4.12
N/A
Revenue Next Year
$9.69
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.96
$0.87
52 Week High
$8.47
$3.19

Technical Indicators

Market Signals
Indicator
UFI
MAIA
Relative Strength Index (RSI) 30.46 41.15
Support Level $3.62 N/A
Resistance Level $6.79 $1.47
Average True Range (ATR) 0.26 0.05
MACD -0.07 -0.00
Stochastic Oscillator 9.66 38.89

Price Performance

Historical Comparison
UFI
MAIA

About UFI Unifi Inc. New

Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: